News
Honeywell and Recipharm to speed development of inhalers with a near – zero global warming potential propellant
Honeywell and global contract development and manufacturing organization (CDMO) Recipharm have announced a commercial partnership that will speed the development of pressurized metered dose inhalers (pMDIs) that use Honeywell’s near-zero global warming potential (GWP) propellant.
As many as 384 million...
BioPharma
Overcoming Challenges In Biopharma Novel Drug Manufacturing
The biopharmaceutical sector is undergoing a significant transformation in treating complex diseases, especially in oncology, driven by innovative drug approaches. This shift entails personalized therapies, combination treatments, and novel go-to-market strategies to address specific patient groups. As the industry...
Drug Research
Unlocking Value-Based Pricing Strategies In Pharma CDMOs
Contract Development and Manufacturing Organizations (CDMOs), which pharmaceutical companies increasingly delegate product development and manufacturing, operate in a fragmented market undergoing substantial consolidation. Yet, many CDMOs fail to fully capitalize on pricing projects, risking competitiveness. To thrive, they must...
News
Global Vaccine Production Drives Pharmaceutical CDMO Market
According to insights, the pharmaceutical CDMO market is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.29% until 2028. This growth could be attributed to the expanding pharmaceutical sector, driven by the increasing usage of analytics...
Drug Research
Small Molecule Innovator CDMO Market Poised For Huge Growth
The projected worth of the Global Small Molecule Innovator CDMO Market is anticipated to surpass $76.50 billion by 2031, displaying a compounded annual growth rate (CAGR) of 6.1% during the estimated timeframe. Contract Development and Manufacturing Organizations (CDMOs) offer...
Drug Research
Parexel, Partex Partner to Accelerate Drug Discovery and Development
Parexel, a CRO providing a full range of Phase I to IV clinical development services, and Partex, a digital pharma platform, entered a strategic alliance designed to leverage artificial intelligence (AI)-powered solutions to accelerate drug discovery and development for...
Drug Research
AGC Biologics, Asahi Kasei Enter Clinical Drug Substance Agreement
AGC Biologics, a global biopharmaceutical CDMO, entered a new agreement with Asahi Kasei Pharma to produce clinical drug substance for antibody-based therapies at AGC Biologics’ Seattle manufacturing site.AGC Biologics will leverage its monoclonal antibody development and manufacturing experience to...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read